Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer

Trastuzumab emtansine showed no disease-free survival or safety advantage over paclitaxel + trastuzumab in the adjuvant setting for patients with stage 1 HER2-positive breast cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news